Pipeline for Ear, Nose and Throat (ENT) Diseases


Lyra’s initial product candidates are focused on rhinologic diseases to provide medicine directly to sinonasal tissues that are not accessible with conventional therapeutic approaches. Our lead product candidate, LYR-210, has completed Phase 2 for chronic rhinosinusitis (CRS). Additional rhinologic indications include CRS patients who have undergone sinus surgery. Lyra’s R&D pipeline also includes other ENT-related indications. Lyra has royalty-free, global rights to all product candidates across all indications.

Back to Top